RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination. - Gruet M; Xu Y; An L; Ma Y; Balcells C; Tyson K; Evangelista LC; Spear S; McKinney F; Babuta J; Bray C; Wickremesinghe C; et al. (Communications biology, 2025)